Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop ...

Vivek Ramaswamy reacted to a list of unnecessary government expenditures that included $33 million of government expenditure to run 'Monkey Island' in South Carolina; $549K to a Russian lab ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

Nov. 4, 2024 — A new study details how climate change transforms coastal wetlands in North Carolina from forest to marshland or even open water, and how satellite imagery may help better direct ...